RLAY: Bull Flag detected on 25 Aug 2026

RLAY is forming a bull flag pattern with strong structure (14.7/15) but moderate breakout (11.2/13) and volume (11.2/12) scores, yielding an overall 70.1 score. Price sits at $19.76 between support at $17.71 and resistance at $20.79. The pattern emerged during a 46% three-month rally that lifted shares 509.88% from the 52-week low. Recent weakness (-4.4% in one week) has compressed the flag, and elevated volume (1.24x average) suggests institutional interest. RSI at 52.98 indicates balanced momentum with room to run higher.

RLAY reported Q2 2026 results on August 6, 2026, with investor focus on updates to its lead asset zovegalisib. In Q1 2026 results released May 5, the company won FDA Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer. Management highlighted promising data supporting development of the zovegalisib plus atirmociclib triplet combination in frontline breast cancer. Recent earnings-beat optimism and strong share price run suggest expectations are already elevated. A fresh $175 million equity raise underlines the company is funding an unprofitable model with future financing and trial risk in view. The Health Care sector regime is bullish (+0.92), supporting biotech strength.

A successful bull flag breakout would see RLAY close decisively above resistance at $20.79 on volume exceeding the 1.24x ratio. The measured move target is $20.41 conservatively, with historical bull flags often extending 50-100% of the preceding rally amplitude. The pattern invalidates on a close below key support at $17.71. The 74.17% win probability suggests favorable odds, though biotech volatility (38.5% annualized) can accelerate both breakout and breakdown moves. Volume confirmation remains critical given the moderate breakout score.

Clinical-stage biotech carries inherent execution risk; zovegalisib Phase 3 ReDiscover-2 trial results remain the primary catalyst and potential volatility driver. Elevated expectations can amplify impact of modest data or guidance surprises. Historically, most RLAY earnings days saw negative 24-hour moves despite positive cash runway updates, creating a news-sensitive but volatile pattern. The company has undergone restructuring with workforce reductions announced. Macro regime is bearish (-0.28) despite sector bullishness, creating crosscurrent risk. ATR at 0.95 (4.81% daily volatility) suggests sharp intraday reversals are possible on clinical updates or market rotation.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.